{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:15:47Z","timestamp":1791346547381,"version":"4.3.1"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EB026468\u201302"],"award-info":[{"award-number":["R01EB026468\u201302"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32HL007088\u201345"],"award-info":[{"award-number":["T32HL007088\u201345"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG3TR002851\u201301"],"award-info":[{"award-number":["UG3TR002851\u201301"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jconrel.2020.09.003","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T11:24:29Z","timestamp":1599132269000},"page":"788-800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors"],"prefix":"10.1016","volume":"327","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7378-4940","authenticated-orcid":false,"given":"Paul","family":"Boucher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3802-6014","authenticated-orcid":false,"given":"David T.","family":"Curiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2020.09.003_bb0005","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan4672","article-title":"Gene therapy comes of age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0010","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2018.0087","article-title":"Origins and evolution of CRISPR-Cas systems","volume":"374","author":"Koonin","year":"2019","journal-title":"Philosophical Trans. Royal Soc. B: Biol. Sci."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0015","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0020","doi-asserted-by":"crossref","first-page":"144636","DOI":"10.1016\/j.gene.2020.144636","article-title":"Medical applications of clustered regularly interspaced short palindromic repeats (CRISPR\/Cas) tool: a comprehensive overview","volume":"745","author":"Araldi","year":"2020","journal-title":"Gene."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0025","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1111\/jcmm.14916","article-title":"CRISPR\/Cas9-mediated genome editing: From basic research to translational medicine","volume":"24","author":"Jacinto","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0030","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR\u2013Cas9 structures and mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu. Rev. Biophys."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0035","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nbt.2842","article-title":"CRISPR-Cas systems for editing, regulating and targeting genomes","volume":"32","author":"Sander","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0040","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1126\/science.aau1549","article-title":"Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy","volume":"362","author":"Amoasii","year":"2018","journal-title":"Science."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0045","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-019-0738-2","article-title":"Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy","volume":"26","author":"Moretti","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0050","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41580-019-0131-5","article-title":"The next generation of CRISPR\u2013Cas technologies and applications","volume":"20","author":"Pickar-Oliver","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbiotec.2019.11.010","article-title":"Recent advances in CRISPR\/Cas9-mediated knock-ins in mammalian cells","volume":"308","author":"Banan","year":"2020","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0060","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3390\/cells9051318","article-title":"Improving precise CRISPR genome editing by small molecules: is there a magic potion?","volume":"9","author":"Bischoff","year":"2020","journal-title":"Cells."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0065","author":"CRISPR Therapeutics"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0070","series-title":"Creating transformative gene-based medicines for serious diseases: Corporate Overview","author":"CRISPR Therapeutics","year":"2020"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0075","series-title":"Research and Pipeline","first-page":"1","author":"Editas Medicine","year":"2017"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0080","author":"Zuris"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0085","author":"Heath"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0090","author":"Dass"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0095","author":"Editas Medicine"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0100","author":"Intellia Therapeutics"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0105","author":"Schultes"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0110","author":"Therapeutics"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0115","author":"Beam Therapeutics"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0120","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cell.2014.02.001","article-title":"Crystal structure of Cas9 in complex with guide RNA and target DNA","volume":"156","author":"Nishimasu","year":"2014","journal-title":"Cell."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0125","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/pro.3235","article-title":"UCSF ChimeraX: meeting modern challenges in visualization and analysis","volume":"27","author":"Goddard","year":"2018","journal-title":"Protein Sci."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0130","doi-asserted-by":"crossref","first-page":"144636","DOI":"10.1016\/j.gene.2020.144636","article-title":"Medical applications of clustered regularly interspaced short palindromic repeats (CRISPR\/Cas) tool: a comprehensive overview","volume":"745","author":"Araldi","year":"2020","journal-title":"Gene."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0140","doi-asserted-by":"crossref","first-page":"119711","DOI":"10.1016\/j.biomaterials.2019.119711","article-title":"Ex vivo cell-based CRISPR\/Cas9 genome editing for therapeutic applications","volume":"234","author":"Li","year":"2020","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0145","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0150","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.stem.2017.10.010","article-title":"Hematopoietic stem cell gene therapy: progress and lessons learned","volume":"21","author":"Morgan","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0155","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1002\/1873-3468.13668","article-title":"Adenovirus vectors in hematopoietic stem cell genome editing","volume":"593","author":"Li","year":"2019","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0160","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/17425247.2018.1517746","article-title":"Delivery approaches for CRISPR\/Cas9 therapeutics in vivo: advances and challenges","volume":"15","author":"Luther","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0165","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0170","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1039\/D0TB00207K","article-title":"Lipid and polymer mediated CRISPR\/Cas9 gene editing","volume":"8","author":"Gong","year":"2020","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0175","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.tibtech.2018.08.010","article-title":"Non-viral delivery to enable genome editing","volume":"37","author":"Rui","year":"2019","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0180","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cell.2020.03.023","article-title":"CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors","volume":"181","author":"Wang","year":"2020","journal-title":"Cell."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0185","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ymthe.2004.09.011","article-title":"Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective","volume":"10","author":"Carter","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0190","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0195","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/1566523214666140302193709","article-title":"Basic Biology of Adeno-Associated Virus (AAV) Vectors Used in Gene Therapy","volume":"14","author":"Balakrishnan","year":"2014","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0200","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.ymthe.2019.08.006","article-title":"Targeted integration and High-level transgene expression in AAVS1 transgenic mice after in vivo HSC transduction with HDAd5\/35++ vectors","volume":"27","author":"Li","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0205","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0210","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrd.2018.110","article-title":"Gene therapy for neurological disorders: progress and prospects","volume":"17","author":"Deverman","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0215","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0220","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11481-016-9724-3","article-title":"Destination brain: the past, present, and future of therapeutic gene delivery","volume":"12","author":"Joshi","year":"2017","journal-title":"J. NeuroImmune Pharmacol."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0225","doi-asserted-by":"crossref","first-page":"7228","DOI":"10.1523\/JNEUROSCI.17-19-07228.1997","article-title":"Phenotypic alteration of astrocytes induced by ciliary neurotrophic factor in the intact adult brain, as revealed by adenovirus-mediated gene transfer","volume":"17","author":"Lisovoski","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0230","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s10571-011-9725-y","article-title":"Adenoviral astrocyte-specific expression of BDNF in the striata of mice transgenic for Huntington\u2019s disease delays the onset of the motor phenotype","volume":"31","author":"Arregui","year":"2011","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0235","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/ng1179","article-title":"AAV serotype 2 vectors preferentially integrate into active genes in mice","volume":"34","author":"Nakai","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0240","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3389","article-title":"Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas","volume":"47","author":"Nault","year":"2015","journal-title":"Nat. Genet."},{"issue":"80","key":"10.1016\/j.jconrel.2020.09.003_bb0245","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1126\/science.1142658","article-title":"AAV vector integration sites in mouse hepatocellular carcinoma","volume":"317","author":"Donsante","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0250","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Ther. Method Clin. Dev."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/c110beed-3cac-48db-9039-ba4498d5db50","article-title":"Modification of Ad5 Hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses","volume":"7","author":"Bruder","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0260","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2016.07.004","article-title":"Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery","volume":"237","author":"Rojas","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0265","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00265-20","article-title":"A new gorilla adenoviral vector with natural lung tropism avoids liver toxicity and is amenable to capsid engineering and vector retargeting","volume":"94","author":"Lu","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0270","doi-asserted-by":"crossref","first-page":"23866","DOI":"10.1073\/pnas.1918306116","article-title":"Gene therapy successes point to better therapies","volume":"116","author":"Dolgin","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0275","series-title":"Methods in Molecular Biology","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-4939-9139-6_2","article-title":"Design of AAV vectors for delivery of large or multiple transgenes","author":"Patel","year":"2019"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0280","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: precision chemistry on the genome and transcriptome of living cells","volume":"19","author":"Rees","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0285","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0290","series-title":"Addgene: pCMV-PE2","year":"2019"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0295","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1134\/S0006297916070063","article-title":"Viral vectors for gene therapy: current state and clinical perspectives","volume":"81","author":"Lukashev","year":"2016","journal-title":"Biochem. Mosc."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0300","series-title":"Advances in Cancer Research","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/B978-0-12-398342-8.00002-1","article-title":"Adenovirus strategies for tissue-specific targeting","author":"Beatty","year":"2012"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0305","series-title":"Proceedings of the National Academy of Sciences of the United States of America","first-page":"2509","article-title":"A simplified system for generating recombinant adenoviruses","author":"He","year":"1998"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0310","series-title":"Adenoviral Vectors for Gene Therapy","first-page":"423","article-title":"Helper-dependent adenoviral vectors","author":"Brunetti-Pierri","year":"2016"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0315","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.omtn.2018.05.006","article-title":"One-vector system for multiplexed CRISPR\/Cas9 against hepatitis B virus cccDNA utilizing High-capacity adenoviral vectors","volume":"12","author":"Schiwon","year":"2018","journal-title":"Mol. Ther. Nucleic Acids."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0320","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1182\/bloodadvances.2019000706","article-title":"High-level protein production in erythroid cells derived from in vivo transduced hematopoietic stem cells","volume":"3","author":"Wang","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0325","author":"Gall"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0330","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00850-17","article-title":"Atomic Structures of Minor Proteins VI and VII in Human Adenovirus","volume":"91","author":"Dai","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0335","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/44880","article-title":"A triple \u03b2-spiral in the adenovirus fibre shaft reveals a new structural motif for a fibrous protein","volume":"401","author":"van Raaij","year":"1999","journal-title":"Nature."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0340","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-08599-y","article-title":"Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions","volume":"10","author":"Baker","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0345","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.omtm.2020.01.014","article-title":"A single \u201call-in-one\u201d helper-dependent adenovirus to deliver donor DNA and CRISPR\/Cas9 for efficient homology-directed repair","volume":"17","author":"Palmer","year":"2020","journal-title":"Mol. Ther. Method Clin. Dev."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0350","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","article-title":"Adenovirus serotype 5 Hexon mediates liver gene transfer","volume":"132","author":"Waddington","year":"2008","journal-title":"Cell."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0355","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.virol.2013.09.020","article-title":"Retargeting of gene expression using endothelium specific hexon modified adenoviral vector","volume":"447","author":"Kaliberov","year":"2013","journal-title":"Virology."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0360","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1182\/blood-2016-04-711580","article-title":"In vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors","volume":"128","author":"Richter","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0365","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","article-title":"Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity","volume":"77","author":"Vogels","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0370","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood-2009-03-208835","article-title":"Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer","volume":"114","author":"Alba","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0375","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00265-20","article-title":"A new gorilla adenoviral vector with natural lung tropism avoids liver toxicity and is amenable to capsid engineering and Vector retargeting","volume":"94","author":"Lu","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0380","series-title":"Adenoviral Vectors for Gene Therapy","first-page":"27","article-title":"Biology of adenovirus cell entry: receptors, pathways, mechanisms","author":"Luisoni","year":"2016"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0385","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/sj.gt.3300941","article-title":"Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector","volume":"6","author":"Reynolds","year":"1999","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0390","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1128\/JVI.74.6.2567-2583.2000","article-title":"Efficient gene transfer into human CD34+ cells by a retargeted adenovirus vector","volume":"74","author":"Shayakhmetov","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0395","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.ymthe.2004.02.006","article-title":"Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule","volume":"9","author":"Pereboev","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0400","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1128\/JVI.74.15.6875-6884.2000","article-title":"Ectodomain of Coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells","volume":"74","author":"Dmitriev","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0405","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2147\/OV.S112107","article-title":"CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter","volume":"5","author":"Bhatia","year":"2016","journal-title":"Oncol. Virother."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0410","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10060201","article-title":"Designer oncolytic adenovirus: coming of age","volume":"10","author":"Baker","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0415","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/hum.2011.016","article-title":"A transductionally retargeted adenoviral vector for virotherapy of her2\/neu-expressing prostate cancer","volume":"23","author":"Magnusson","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0420","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/cgt.2008.75","article-title":"Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity","volume":"16","author":"Piao","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0425","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41417-017-0002-1","article-title":"Development of an adenovirus vector vaccine platform for targeting dendritic cells","volume":"25","author":"Sharma","year":"2018","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0430","doi-asserted-by":"crossref","first-page":"8221","DOI":"10.1128\/jvi.71.11.8221-8229.1997","article-title":"Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins","volume":"71","author":"Wickham","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0435","doi-asserted-by":"crossref","first-page":"8621","DOI":"10.1128\/JVI.76.17.8621-8631.2002","article-title":"Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the Fiber protein","volume":"76","author":"Belousova","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0440","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/gt.2010.138","article-title":"Physiological and tissue-specific vectors for treatment of inherited diseases","volume":"18","author":"Toscano","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0450","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/CIRCRESAHA.115.304351","article-title":"Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing","volume":"115","author":"Ding","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0455","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/hum.2015.087","article-title":"Adenovirus-mediated somatic genome editing of Pten by CRISPR\/Cas9 in mouse liver in spite of Cas9-specific immune responses","volume":"26","author":"Wang","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0460","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2018-03-838540","article-title":"Reactivation of g-globin in adult b-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing","volume":"131","author":"Li","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0465","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ebiom.2018.02.015","article-title":"Therapeutic genome editing with CRISPR\/Cas9 in a humanized mouse model ameliorates \u03b11-antitrypsin deficiency phenotype","volume":"29","author":"Bjursell","year":"2018","journal-title":"EBioMedicine."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0470","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/mt.2015.192","article-title":"CRISPR-mediated genome editing restores dystrophin expression and function in mdx mice","volume":"24","author":"Xu","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0475","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41591-019-0401-y","article-title":"Highly efficient therapeutic gene editing of human hematopoietic stem cells","volume":"25","author":"Wu","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0480","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jconrel.2019.02.009","article-title":"Long-term correction of hemophilia B using adenoviral delivery of CRISPR\/Cas9","volume":"298","author":"Stephens","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0485","doi-asserted-by":"crossref","first-page":"477","DOI":"10.15252\/emmm.201506039","article-title":"CRISPR \/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse","volume":"8","author":"Guan","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0490","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41434-018-0003-1","article-title":"Targeted in vivo knock-in of human alpha-1-antitrypsin cDNA using adenoviral delivery of CRISPR\/Cas9","volume":"25","author":"Stephens","year":"2018","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0495","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1093\/nar\/gkx490","article-title":"Selective disruption of an oncogenic mutant allele by CRISPR\/Cas9 induces efficient tumor regressionitle","volume":"45","author":"Koo","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0500","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1021\/acschembio.7b01058","article-title":"Generation of Optogenetically modified adenovirus vector for spatiotemporally controllable gene therapy","volume":"13","author":"Takayama","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0505","doi-asserted-by":"crossref","first-page":"29220","DOI":"10.18632\/oncotarget.25678","article-title":"Development of an integrated CRISPRi targeting \u25b5Np63 for treatment of squamous cell carcinoma","volume":"9","author":"Yoshida","year":"2018","journal-title":"Oncotarget."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0510","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.7150\/thno.42325","article-title":"Selective targeting of the oncogenic KRAS G12S mutant allele by CRISPR\/Cas9 induces efficient tumor regression","volume":"10","author":"Gao","year":"2020","journal-title":"Theranostics."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0515","series-title":"Search of: adenovirus OR adv OR adenoviral OR ad | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Cancer NOT communicable - List Results - ClinicalTrials.gov","year":"2020"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0520","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2013.06.044","article-title":"CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes","volume":"154","author":"Gilbert","year":"2013","journal-title":"Cell."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0525","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nbt.2675","article-title":"CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering","volume":"31","author":"Mali","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0530","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nmeth.2600","article-title":"RNA-guided gene activation by CRISPR-Cas9-based transcription factors","volume":"10","author":"Perez-Pinera","year":"2013","journal-title":"Nat. Methods"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0535","series-title":"A Self-restricted CRISPR System to Reduce Off-target Effects","author":"Chen","year":"2016"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0540","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.omtm.2018.04.008","article-title":"HDAd5\/35++ adenovirus vector expressing anti-CRISPR peptides decreases CRISPR\/Cas9 toxicity in human hematopoietic stem cells","volume":"9","author":"Li","year":"2018","journal-title":"Mol. Ther. Method Clin. Dev."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0545","first-page":"1","article-title":"Precision oncology- the future of personalized cancer medicine?","volume":"1","author":"Bode","year":"2017","journal-title":"Npj Precision Oncol."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0550","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bbcan.2009.11.002","article-title":"Tumor heterogeneity: causes and consequences","volume":"1805","author":"Marusyk","year":"2010","journal-title":"Biochimica et Biophysica Acta - Rev. Cancer."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0555","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.virol.2006.01.037","article-title":"An adenovirus serotype 5 vector with fibers derived from ovine atadenovirus demonstrates CAR-independent tropism and unique biodistribution in mice","volume":"350","author":"Nakayama","year":"2006","journal-title":"Virology."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0560","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/cas.13228","article-title":"Recent advances in genetic modification of adenovirus vectors for cancer treatment","volume":"108","author":"Yamamoto","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0565","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1158\/1535-7163.MCT-19-0768","article-title":"Targeting tumor neoangiogenesis via targeted adenoviral vector to achieve effective cancer gene therapy for disseminated neoplastic disease","volume":"19","author":"Lee","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0570","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083933","article-title":"Transcriptional targeting of primary and metastatic tumor neovasculature by an adenoviral type 5 roundabout4 vector in mice","volume":"8","author":"Lu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2020.09.003_bb0575","doi-asserted-by":"crossref","first-page":"12272","DOI":"10.18632\/oncotarget.14699","article-title":"A new model of multi-visceral and bone metastatic prostate cancer with perivascular niche targeting by a novel endothelial specific adenoviral vector","volume":"8","author":"Lu","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0580","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aad5227","article-title":"Rationally engineered Cas9 nucleases with improved specificity","volume":"351","author":"Slaymaker","year":"2016","journal-title":"Science."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0585","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nbt.1717","article-title":"Genomic safe harbors permit high \u03b2-globin transgene expression in thalassemia induced pluripotent stem cells","volume":"29","author":"Papapetrou","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0590","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12896-016-0234-4","article-title":"Efficient generation of Rosa26 knock-in mice using CRISPR\/Cas9 in C57BL\/6 zygotes","volume":"16","author":"Chu","year":"2016","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0595","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/nrg.2016.28","article-title":"Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases","volume":"17","author":"Tsai","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0600","doi-asserted-by":"crossref","first-page":"7689","DOI":"10.1128\/JVI.77.13.7689-7695.2003","article-title":"Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivo","volume":"77","author":"Ehrhardt","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0605","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR\u2013Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0610","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00109-020-01893-z","article-title":"Mitigating off-target effects in CRISPR\/Cas9-mediated in vivo gene editing","volume":"98","author":"Han","year":"2020","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0615","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.omtm.2019.04.003","article-title":"Production of CRISPR\/Cas9-mediated self-cleaving helper-dependent adenoviruses","volume":"13","author":"Palmer","year":"2019","journal-title":"Mol. Ther. Method Clin. Dev."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0620","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.csbj.2019.07.015","article-title":"Drug inducible CRISPR\/Cas systems","volume":"17","author":"Zhang","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0625","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aad5227","article-title":"Rationally engineered Cas9 nucleases with improved specificity","volume":"351","author":"Slaymaker","year":"2016","journal-title":"Science."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0630","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature16526","article-title":"High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects","volume":"529","author":"Kleinstiver","year":"2016","journal-title":"Nature."},{"key":"10.1016\/j.jconrel.2020.09.003_bb0635","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3390\/ph5121372","article-title":"The liver as a target organ for gene therapy: state of the art, challenges, and future perspectives","volume":"5","author":"Jacobs","year":"2012","journal-title":"Pharmaceuticals."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920305113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920305113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T23:17:21Z","timestamp":1718407041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365920305113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":125,"alternative-id":["S0168365920305113"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.09.003","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}